Skip to main content
Fig. 6 | Experimental Hematology & Oncology

Fig. 6

From: A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models

Fig. 6

42105-74bbz CAR-T cells are not inferior to the 19bbz CAR-T cells in prolonging the survival in a preclinical MCL NSG mouse model. A Mice were engrafted with Mino cells subcutaneously and randomized into groups of 10 for tumor alone (blue), tumor + UTT cells (green), tumor + 19bbz CAR-T cells (black) and tumor + 42105-74bbz CAR-T cells (red). Table (bottom) was a summary of p-values in survival comparisons among all groups. B Mice received 42105-74bbz CAR-T cells had the least median log absolute numbers of tumor cells in blood and spleen harvested when mice reached ERC. While the median log absolute number of circulating CAR-T cells in 74bbz CAR-T cells treated mice was higher than that of 19bbz CAR-T cells treated mice, similar numbers of CAR-Ts in both 19bbz and 74bbz CAR-T cells treated mice were found in spleen

Back to article page